SLC5A2 and hydrops fetalis: Recently, the SGLT2 inhibitor dapagliflozin has been shown to lead to reductions in the risk of death and hospitalisations due to HF in patients with HF with a reduced ejection fraction regardless of the presence of T2D [8].